Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model
Both [<sup>225</sup>Ac]Ac-PSMA-617 and [<sup>177</sup>Lu]Lu-PSMA-617 caused transient hematotoxicity without prolonged effects. The data do not explicitly support the necessity of immunocompetent models for studying therapeutic outcomes in this context. Future studies incorporating immune profiling are warranted to investigate immune system interactions in radioligand therapy further.
Authors
- Giuseppe Carlucci (ORCID: https://orcid.org/0000-0001-7494-335X)
- Marco F. Taddio (ORCID: https://orcid.org/0000-0003-2477-5575)
- Christine E. Mona
- Meryl Maria Vilangattil (ORCID: https://orcid.org/0009-0000-8083-8097)
- Abir Swaidan
- Johannes Czernin
- Jonathan Godinez
Institutions
- UCLA Health (US)
- Molecular Theranostics (United States) (US)
- UCLA Jonsson Comprehensive Cancer Center
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1186/s41181-025-00333-y
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- U.S. Department of Energy
- University of California, Los Angeles